
Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 03/10/2022

COVID-19 Genomics and Precision Public Health Weekly Update Content

- Pathogen and Human Genomics Studies
- Non-Genomics Precision Health Studies
- News, Reviews and Commentaries

Pathogen and Human Genomics Studies

- Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial (<https://www.nature.com/articles/s41591-022-01739-w>)
L Chu et al, Nature Medicine, March 3, 2022

This study shows that a booster injection of mRNA-1273 more than 6 months after completing the primary two-dose series is safe and elicited nAb titers that were statistically significantly higher than the peak titers detected after the primary vaccination series, suggesting that a booster dose of mRNA-1273 might result in increased vaccine effectiveness against infection and disease caused by SARS-CoV-2.

- Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents (<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579?resultClick=1>)
CR Oliveira et al, JAMA Network Open, March 4, 2022

What is the association between the BNT162b2 COVID-19 vaccine and SARS-CoV-2 positivity among adolescents? This case-control study of 542 adolescents was conducted when the Delta variant of SARS-CoV-2 was predominant and within 4 months of the vaccine rollout for adolescents. Overall, the estimated effectiveness of the BNT162b2 vaccine was 91%, with 93% protection against symptomatic infections and 85% effectiveness against asymptomatic infection.

- Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease (<https://www.nature.com/articles/s41588-021-01006-7>)

Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters human host cells via angiotensin-converting enzyme 2 (ACE2). COVID-19 ranges from asymptomatic infection to severe disease, including respiratory failure and death, and has led to more than 5 million deaths worldwide since December 2019⁵. Reported risk factors for severe COVID-19 include male sex, older age, ethnicity, obesity and cardiovascular and respiratory diseases^{6,7,8}, among others. Host genetic factors have also been shown to modulate the risk of infection and disease severity^{9,10,11,12}. The largest human genetics study performed so far included data from 49,562 individuals infected with SARS-CoV-2 and >1.7 million individuals with no record of infection as controls, and identified 13 independent common risk variants¹², many located in or near immune-related genes.

- Factors associated with SARS-CoV-2 transmission in setting of high COVID-19 vaccination coverage: a case-control study. (<https://pubmed.ncbi.nlm.nih.gov/35247046>)
Reid Michael J A et al. American journal of epidemiology 2022 3
- Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. (<https://pubmed.ncbi.nlm.nih.gov/35238329>)
Layan Maylis et al. American journal of epidemiology 2022 3

Compared with unvaccinated and unisolated adult/teenager contacts, vaccination reduced the risk of infection among unisolated adult/teenager contacts above 12 (RR=0.21, 95% CrI credible interval 0.08-0.44) and isolation reduced the risk of infection among unvaccinated adult/teenager (RR=0.12, 95% CrI 0.06-0.21) and child contacts (RR=0.17, 95% CrI 0.08-0.32). Infectivity was reduced in vaccinated cases (RR=0.25, 95% CrI 0.06-0.77). Within households, vaccination reduces both the risk of infection and of transmission if infected.

- Whole genome sequencing reveals host factors underlying critical Covid-19
(<https://www.nature.com/articles/s41586-022-04576-6>)
A Kousathanas et al, Nature, March 7, 2022

Here, we use whole genome sequencing in 7,491 critically-ill cases compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical Covid-19. We identify 16 new independent associations, including variants within genes involved in interferon signalling (IL10RB, PLSCR1), leucocyte differentiation (BCL11A), and blood type antigen secretor status (FUT2). Using transcriptome-wide association and colocalisation to infer the effect of gene expression on disease severity, we find evidence implicating multiple genes, including reduced expression of a membrane flippase (ATP11A), and increased mucin expression (MUC1), in critical disease. Mendelian randomisation provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5, CD209) and coagulation factor F8, all of which are potentially druggable targets.

- Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households (<https://jamanetwork.com/journals/jama/fullarticle/2789920>)

SB Jorgenson et al, JAMA< March 7, 2022

Secondary attack rate was 25.1% (95% CI, 24.4%-25.9%) when the variant of the index case was Omicron, 19.4% (95% CI, 19.0%-19.8%) when it was Delta, and 17.9% (95% CI, 17.5%-18.4%) when it was nonclassified (Table). In the adjusted logistic regression model, the OR of nonindex household members testing positive was 1.52 (95% CI, 1.41-1.64) when the variant of the index case was Omicron and 0.93 (95% CI, 0.88-0.98) when it was nonclassified compared with Delta. Odds ratios were higher for men, unvaccinated individuals, and those older than 30 years, and in week 52.

- Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescents (<https://www.researchsquare.com/article/rs-1327020/v1>)

YL Lau et al, Research Square, March 8, 2022

We conducted a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of these 2 vaccines in healthy adolescents. One-dose BNT162b2 outcomes were also assessed since it had been recommended in some localities due to the risk of myocarditis. Antibodies and T cell immune responses were non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N=116) and CoronaVac (CC, N=123) versus adults after 2 doses of the same vaccine (BB, N=147; CC, N=141) but not in adolescents after 1 dose of BNT162b2 (B, N=116). CC induced SARS-CoV-2 nucleocapsid (N) and N C-terminal domain seroconversion in more adolescents than adults. Adverse reactions were mostly mild for both vaccines and more frequent for BNT162b2. We confirmed higher S, neutralizing, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC

- ACE2 protein expression in lung tissues of severe COVID-19 infection (<https://www.nature.com/articles/s41598-022-07918-6>)

A Gheware et al, Scientific Reports, March 8, 2022

In a total of 55, 44 COVID-19 post-mortem lung samples were tested for ACE2, 36 for CD163, and 26 for CD61, compared to 15 non-covid 19 control lung sections. Quantification of immunostaining, random sampling, and correlation analysis were used to substantiate the morphologic findings. Our results show that ACE2 protein expression was significantly higher in COVID-19 post-mortem lung tissues than in controls, regardless of sample size. Our results show significantly higher ACE2 protein expression in severe COVID-19 disease, correlating with increased macrophage infiltration and microthrombi, suggesting a pathobiological role in disease severity.

- Genetic Predisposition to Coronavirus Disease 2019 in Relation to Ten Cardiovascular Conditions: A Two-Sample Mendelian Randomization Study. (<https://pubmed.ncbi.nlm.nih.gov/35252241>)

Jia Min et al. Frontiers in medicine 2022 3 796165

The long-term health consequences of coronavirus disease 2019 (COVID-19) remain largely unclear. This study aimed to apply the Mendelian randomization (MR) design to estimate the causal

associations between COVID-19 and ten cardiovascular conditions. Our findings provide direct evidence that patients infected with COVID-19 are causally associated with increased risk of cardiovascular disease, especially for major coronary heart disease events and heart failure.

- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
(<https://pubmed.ncbi.nlm.nih.gov/35263534>)

Abu-Raddad Laith J et al. The New England journal of medicine 2022 3

The messenger RNA (mRNA) boosters were highly effective against symptomatic delta infection, but they were less effective against symptomatic omicron infection. However, with both variants, mRNA boosters led to strong protection against Covid-19–related hospitalization and death.

- Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
(<https://pubmed.ncbi.nlm.nih.gov/35263535>)

Takashita Emi et al. The New England journal of medicine 2022 3

The susceptibilities of omicron/BA.2 (NCD1288) to remdesivir, molnupiravir, and nirmatrelvir were similar to those of the ancestral strain and other variants of concern (i.e., 50% inhibitory concentration values for these three agents that differed by factors of 2.5 to 4.5, 0.7 to 1.6, and 1.5 to 3.3, respectively) (Table 1).³ Clinical studies are warranted to determine whether these antiviral therapies are indeed effective against omicron/BA.2 infections. Our data indicate that some therapeutic monoclonal antibodies (REGN10987–REGN10933, COV2-2196–COV2-2130, and S309) have lower neutralizing activity against omicron/BA.2 than against earlier variant strains.

Non-Genomics Precision Health Studies

- Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
(<https://www.nature.com/articles/s41591-022-01739-w>)

L Chu et al, Nature Medicine, March 3, 2022

This study shows that a booster injection of mRNA-1273 more than 6 months after completing the primary two-dose series is safe and elicited nAb titers that were statistically significantly higher than the peak titers detected after the primary vaccination series, suggesting that a booster dose of mRNA-1273 might result in increased vaccine effectiveness against infection and disease caused by SARS-CoV-2.

- Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents
(<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579?resultClick=1>)

CR Oliveira et al, JAMA Network Open, March 4, 2022

What is the association between the BNT162b2 COVID-19 vaccine and SARS-CoV-2 positivity among adolescents? This case-control study of 542 adolescents was conducted when the Delta variant of SARS-CoV-2 was predominant and within 4 months of the vaccine rollout for adolescents. Overall, the

estimated effectiveness of the BNT162b2 vaccine was 91%, with 93% protection against symptomatic infections and 85% effectiveness against asymptomatic infection.

- Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease (<https://www.nature.com/articles/s41588-021-01006-7>)
JE Horowitz et al, Nature Genetics, March 4, 2022

Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters human host cells via angiotensin-converting enzyme 2 (ACE2). COVID-19 ranges from asymptomatic infection to severe disease, including respiratory failure and death, and has led to more than 5 million deaths worldwide since December 2019⁵. Reported risk factors for severe COVID-19 include male sex, older age, ethnicity, obesity and cardiovascular and respiratory diseases^{6,7,8}, among others. Host genetic factors have also been shown to modulate the risk of infection and disease severity^{9,10,11,12}. The largest human genetics study performed so far included data from 49,562 individuals infected with SARS-CoV-2 and >1.7 million individuals with no record of infection as controls, and identified 13 independent common risk variants¹², many located in or near immune-related genes.

- Factors associated with SARS-CoV-2 transmission in setting of high COVID-19 vaccination coverage: a case-control study. (<https://pubmed.ncbi.nlm.nih.gov/35247046>)
Reid Michael J A et al. American journal of epidemiology 2022 3

- Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. (<https://pubmed.ncbi.nlm.nih.gov/35238329>)
Layan Maylis et al. American journal of epidemiology 2022 3

Compared with unvaccinated and unisolated adult/teenager contacts, vaccination reduced the risk of infection among unisolated adult/teenager contacts above 12 (RR=0.21, 95% CrI credible interval 0.08-0.44) and isolation reduced the risk of infection among unvaccinated adult/teenager (RR=0.12, 95% CrI 0.06-0.21) and child contacts (RR=0.17, 95% CrI 0.08-0.32). Infectivity was reduced in vaccinated cases (RR=0.25, 95% CrI 0.06-0.77). Within households, vaccination reduces both the risk of infection and of transmission if infected.

- Whole genome sequencing reveals host factors underlying critical Covid-19 (<https://www.nature.com/articles/s41586-022-04576-6>)
A Kousathanas et al, Nature, March 7, 2022

Here, we use whole genome sequencing in 7,491 critically-ill cases compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical Covid-19. We identify 16 new independent associations, including variants within genes involved in interferon signalling (IL10RB, PLSCR1), leucocyte differentiation (BCL11A), and blood type antigen secretor status (FUT2). Using transcriptome-wide association and colocalisation to infer the effect of gene expression on disease severity, we find evidence implicating multiple genes, including reduced

expression of a membrane flippase (ATP11A), and increased mucin expression (MUC1), in critical disease. Mendelian randomisation provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5, CD209) and coagulation factor F8, all of which are potentially druggable targets.

- Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households (<https://jamanetwork.com/journals/jama/fullarticle/2789920>)

SB Jorgenson et al, JAMA< March 7, 2022

Secondary attack rate was 25.1% (95% CI, 24.4%-25.9%) when the variant of the index case was Omicron, 19.4% (95% CI, 19.0%-19.8%) when it was Delta, and 17.9% (95% CI, 17.5%-18.4%) when it was nonclassified (Table). In the adjusted logistic regression model, the OR of nonindex household members testing positive was 1.52 (95% CI, 1.41-1.64) when the variant of the index case was Omicron and 0.93 (95% CI, 0.88-0.98) when it was nonclassified compared with Delta. Odds ratios were higher for men, unvaccinated individuals, and those older than 30 years, and in week 52.

- Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescents (<https://www.researchsquare.com/article/rs-1327020/v1>)

YL Lau et al, Research Square, March 8, 2022

We conducted a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of these 2 vaccines in healthy adolescents. One-dose BNT162b2 outcomes were also assessed since it had been recommended in some localities due to the risk of myocarditis. Antibodies and T cell immune responses were non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N=116) and CoronaVac (CC, N=123) versus adults after 2 doses of the same vaccine (BB, N=147; CC, N=141) but not in adolescents after 1 dose of BNT162b2 (B, N=116). CC induced SARS-CoV-2 nucleocapsid (N) and N C-terminal domain seroconversion in more adolescents than adults. Adverse reactions were mostly mild for both vaccines and more frequent for BNT162b2. We confirmed higher S, neutralizing, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC

- ACE2 protein expression in lung tissues of severe COVID-19 infection (<https://www.nature.com/articles/s41598-022-07918-6>)

A Gheware et al, Scientific Reports, March 8, 2022

In a total of 55, 44 COVID-19 post-mortem lung samples were tested for ACE2, 36 for CD163, and 26 for CD61, compared to 15 non-covid 19 control lung sections. Quantification of immunostaining, random sampling, and correlation analysis were used to substantiate the morphologic findings. Our results show that ACE2 protein expression was significantly higher in COVID-19 post-mortem lung tissues than in controls, regardless of sample size. Our results show significantly higher ACE2 protein expression in severe COVID-19 disease, correlating with increased macrophage infiltration and microthrombi, suggesting a pathobiological role in disease severity.

- Genetic Predisposition to Coronavirus Disease 2019 in Relation to Ten Cardiovascular Conditions: A Two-Sample Mendelian Randomization Study. (<https://pubmed.ncbi.nlm.nih.gov/35252241>)

Jia Min et al. *Frontiers in medicine* 2022 3 796165

The long-term health consequences of coronavirus disease 2019 (COVID-19) remain largely unclear. This study aimed to apply the Mendelian randomization (MR) design to estimate the causal associations between COVID-19 and ten cardiovascular conditions. Our findings provide direct evidence that patients infected with COVID-19 are causally associated with increased risk of cardiovascular disease, especially for major coronary heart disease events and heart failure.

- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.

(<https://pubmed.ncbi.nlm.nih.gov/35263534>)

Abu-Raddad Laith J et al. *The New England journal of medicine* 2022 3

The messenger RNA (mRNA) boosters were highly effective against symptomatic delta infection, but they were less effective against symptomatic omicron infection. However, with both variants, mRNA boosters led to strong protection against Covid-19–related hospitalization and death.

- Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.

(<https://pubmed.ncbi.nlm.nih.gov/35263535>)

Takashita Emi et al. *The New England journal of medicine* 2022 3

The susceptibilities of omicron/BA.2 (NCD1288) to remdesivir, molnupiravir, and nirmatrelvir were similar to those of the ancestral strain and other variants of concern (i.e., 50% inhibitory concentration values for these three agents that differed by factors of 2.5 to 4.5, 0.7 to 1.6, and 1.5 to 3.3, respectively) (Table 1).³ Clinical studies are warranted to determine whether these antiviral therapies are indeed effective against omicron/BA.2 infections. Our data indicate that some therapeutic monoclonal antibodies (REGN10987–REGN10933, COV2-2196–COV2-2130, and S309) have lower neutralizing activity against omicron/BA.2 than against earlier variant strains.

News, Reviews and Commentaries

- Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

(<https://www.nature.com/articles/s41591-022-01739-w>)

L Chu et al, *Nature Medicine*, March 3, 2022

This study shows that a booster injection of mRNA-1273 more than 6 months after completing the primary two-dose series is safe and elicited nAb titers that were statistically significantly higher than the peak titers detected after the primary vaccination series, suggesting that a booster dose of mRNA-1273 might result in increased vaccine effectiveness against infection and disease caused by SARS-CoV-2.

- Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents (<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789579?resultClick=1>)
CR Oliveira et al, JAMA Network Open, March 4, 2022

What is the association between the BNT162b2 COVID-19 vaccine and SARS-CoV-2 positivity among adolescents? This case-control study of 542 adolescents was conducted when the Delta variant of SARS-CoV-2 was predominant and within 4 months of the vaccine rollout for adolescents. Overall, the estimated effectiveness of the BNT162b2 vaccine was 91%, with 93% protection against symptomatic infections and 85% effectiveness against asymptomatic infection.

- Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease (<https://www.nature.com/articles/s41588-021-01006-7>)
JE Horowitz et al, Nature Genetics, March 4, 2022

Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters human host cells via angiotensin-converting enzyme 2 (ACE2). COVID-19 ranges from asymptomatic infection to severe disease, including respiratory failure and death, and has led to more than 5 million deaths worldwide since December 2019⁵. Reported risk factors for severe COVID-19 include male sex, older age, ethnicity, obesity and cardiovascular and respiratory diseases^{6,7,8}, among others. Host genetic factors have also been shown to modulate the risk of infection and disease severity^{9,10,11,12}. The largest human genetics study performed so far included data from 49,562 individuals infected with SARS-CoV-2 and >1.7 million individuals with no record of infection as controls, and identified 13 independent common risk variants¹², many located in or near immune-related genes.

- Factors associated with SARS-CoV-2 transmission in setting of high COVID-19 vaccination coverage: a case-control study. (<https://pubmed.ncbi.nlm.nih.gov/35247046>)
Reid Michael J A et al. American journal of epidemiology 2022 3

- Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. (<https://pubmed.ncbi.nlm.nih.gov/35238329>)
Layan Maylis et al. American journal of epidemiology 2022 3

Compared with unvaccinated and unisolated adult/teenager contacts, vaccination reduced the risk of infection among unisolated adult/teenager contacts above 12 (RR=0.21, 95% CrI credible interval 0.08-0.44) and isolation reduced the risk of infection among unvaccinated adult/teenager (RR=0.12, 95% CrI 0.06-0.21) and child contacts (RR=0.17, 95% CrI 0.08-0.32). Infectivity was reduced in vaccinated cases (RR=0.25, 95% CrI 0.06-0.77). Within households, vaccination reduces both the risk of infection and of transmission if infected.

- Whole genome sequencing reveals host factors underlying critical Covid-19 (<https://www.nature.com/articles/s41586-022-04576-6>)
A Kousathanas et al, Nature, March 7, 2022

Here, we use whole genome sequencing in 7,491 critically-ill cases compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical Covid-19. We identify 16 new independent associations, including variants within genes involved in interferon signalling (IL10RB, PLSCR1), leucocyte differentiation (BCL11A), and blood type antigen secretor status (FUT2). Using transcriptome-wide association and colocalisation to infer the effect of gene expression on disease severity, we find evidence implicating multiple genes, including reduced expression of a membrane flippase (ATP11A), and increased mucin expression (MUC1), in critical disease. Mendelian randomisation provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5, CD209) and coagulation factor F8, all of which are potentially druggable targets.

- Secondary Attack Rates for Omicron and Delta Variants of SARS-CoV-2 in Norwegian Households (<https://jamanetwork.com/journals/jama/fullarticle/2789920>)
SB Jorgenson et al, JAMA< March 7, 2022

Secondary attack rate was 25.1% (95% CI, 24.4%-25.9%) when the variant of the index case was Omicron, 19.4% (95% CI, 19.0%-19.8%) when it was Delta, and 17.9% (95% CI, 17.5%-18.4%) when it was nonclassified (Table). In the adjusted logistic regression model, the OR of nonindex household members testing positive was 1.52 (95% CI, 1.41-1.64) when the variant of the index case was Omicron and 0.93 (95% CI, 0.88-0.98) when it was nonclassified compared with Delta. Odds ratios were higher for men, unvaccinated individuals, and those older than 30 years, and in week 52.

- Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescents (<https://www.researchsquare.com/article/rs-1327020/v1>)
YL Lau et al, Research Square, March 8, 2022

We conducted a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of these 2 vaccines in healthy adolescents. One-dose BNT162b2 outcomes were also assessed since it had been recommended in some localities due to the risk of myocarditis. Antibodies and T cell immune responses were non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N=116) and CoronaVac (CC, N=123) versus adults after 2 doses of the same vaccine (BB, N=147; CC, N=141) but not in adolescents after 1 dose of BNT162b2 (B, N=116). CC induced SARS-CoV-2 nucleocapsid (N) and N C-terminal domain seroconversion in more adolescents than adults. Adverse reactions were mostly mild for both vaccines and more frequent for BNT162b2. We confirmed higher S, neutralizing, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC

- ACE2 protein expression in lung tissues of severe COVID-19 infection (<https://www.nature.com/articles/s41598-022-07918-6>)
A Gheware et al, Scientific Reports, March 8, 2022

In a total of 55, 44 COVID-19 post-mortem lung samples were tested for ACE2, 36 for CD163, and 26 for CD61, compared to 15 non-covid 19 control lung sections. Quantification of immunostaining,

random sampling, and correlation analysis were used to substantiate the morphologic findings. Our results show that ACE2 protein expression was significantly higher in COVID-19 post-mortem lung tissues than in controls, regardless of sample size. Our results show significantly higher ACE2 protein expression in severe COVID-19 disease, correlating with increased macrophage infiltration and microthrombi, suggesting a pathobiological role in disease severity.

- Genetic Predisposition to Coronavirus Disease 2019 in Relation to Ten Cardiovascular Conditions: A Two-Sample Mendelian Randomization Study. (<https://pubmed.ncbi.nlm.nih.gov/35252241>)
Jia Min et al. Frontiers in medicine 2022 3 796165

The long-term health consequences of coronavirus disease 2019 (COVID-19) remain largely unclear. This study aimed to apply the Mendelian randomization (MR) design to estimate the causal associations between COVID-19 and ten cardiovascular conditions. Our findings provide direct evidence that patients infected with COVID-19 are causally associated with increased risk of cardiovascular disease, especially for major coronary heart disease events and heart failure.

- Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. (<https://pubmed.ncbi.nlm.nih.gov/35263534>)
Abu-Raddad Laith J et al. The New England journal of medicine 2022 3

The messenger RNA (mRNA) boosters were highly effective against symptomatic delta infection, but they were less effective against symptomatic omicron infection. However, with both variants, mRNA boosters led to strong protection against Covid-19–related hospitalization and death.

- Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. (<https://pubmed.ncbi.nlm.nih.gov/35263535>)
Takashita Emi et al. The New England journal of medicine 2022 3

The susceptibilities of omicron/BA.2 (NCD1288) to remdesivir, molnupiravir, and nirmatrelvir were similar to those of the ancestral strain and other variants of concern (i.e., 50% inhibitory concentration values for these three agents that differed by factors of 2.5 to 4.5, 0.7 to 1.6, and 1.5 to 3.3, respectively) (Table 1).³ Clinical studies are warranted to determine whether these antiviral therapies are indeed effective against omicron/BA.2 infections. Our data indicate that some therapeutic monoclonal antibodies (REGN10987–REGN10933, COV2-2196–COV2-2130, and S309) have lower neutralizing activity against omicron/BA.2 than against earlier variant strains.

Disclaimer: Articles listed in COVID-19 Genomics and Precision Public Health Weekly Update are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

Page last reviewed: Oct 1, 2021

Page last updated: Mar 10, 2022

Content source: Office of Genomics and Precision Public Health (<http://www.cdc.gov/genomics/>), CDC Office of Science (<https://www.cdc.gov/od/science/index.htm>)